Listen
XARELTO
-
Opinions on drugs -
Posted on
Mar 14 2012
- Updated on
Apr 18 2012
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance (B/14, B/28 and B/42 for the 15 mg/tablet dosage and B/14 and B/28 for the 20 mg/tablet dosage) and approved for hospital use (B/10 and B/100 for both dosages) in the extension of indication: “Treatment of deep venous thrombosis (DVP) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVP in adults”.
-
Clinical Benefit
| Substantial |
The actual benefit of XARELTO (rivaroxaban) is substantial in the treatment of deep venous thrombosis (DVT) and in the prevention of recurrence of DVT and pulmonary embolism (PE) following acute DVT in adults. |
Clinical Added Value
| no clinical added value |
XARELTO does not provide an improvement in actual benefit (IAB level V) in the treatment of acute deep venous thrombosis and in the prevention of the recurrence of DVT and pulmonary embolism (PE). |
English version
Contact Us
Évaluation des médicaments
